Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo

Bristol’s Relatlimab/Opdivo (anti-LAG-3/PD-1) therapy is poised to make inroads into its own Opdivo/Yervoy (PD-1/CTLA-4) inhibitor combination share for malignant melanoma. As part of our Drugs to Watch™ series, Clarivate oncology experts Liseth Parra and Rachel Webster review new data shared at ASCO 2021, and implications for patients and life sciences companies.   Compelling Phase III […]

KEYNOTE-564 paves future role for immunotherapy in adjuvant renal cell carcinoma

Merck &Co.’s Keytruda has practice-changing potential as adjuvant therapy for renal cell carcinoma. As part of our Drugs to Watch™ series, Clarivate oncology experts Priyanka Mehra and Sorcha Cassidy review new data shared at the 2021 ASCO Annual Meeting, and implications for patients and life sciences companies.   The renal cell carcinoma treatment landscape continues […]

Roche’s Tecentriq shows promise in resectable NSCLC: key takeaways for the market

Tecentriq, Roche’s flagship anti-PD-L1 therapy, gets one step closer to becoming the first immunotherapy to gain approval as adjuvant therapy in resectable non-small cell lung cancer (NSCLC). As part of our Drugs to Watch™ series, Clarivate oncology experts Arman Esfandiari, Amardeep Singh and Khurram Nawaz review new data shared at ASCO 2021, and implications for […]

Six oncology breakthroughs from Mainland China: Takeaways from ASCO 2021

Clarivate oncology experts analyzed ASCO 2021 abstracts from Mainland China to highlight key trends and breakthrough treatments that are expected to impact the oncology landscape. Mainland Chinese companies were strongly represented at the 2021 ASCO Annual Meeting. As part of our Drugs to Watch™ series spotlighting therapies expected to have significant impact on drug landscapes, […]

Top 10 oncology breakthroughs shared at ASCO 2021

Clarivate oncology experts analyzed more than 2,400 ASCO abstracts and selected the top 10 based on their expected impact on the drug treatment landscape. In the following article, we share our analysis of these exciting breakthroughs, data and takeaways for life sciences executives.   “Equity: Every Patient. Everyday. Everywhere” The ASCO Annual Meeting is the […]

Immuno-oncology breakthroughs: from precision medicine to modulating the tumor microenvironment

The European Association for Cancer Research (EACR) explores the most exciting cancer research from Europe and globally. Clarivate Life Sciences Editor Joan Tur reviews the top three trends from their recent immuno-oncology event, and their implications for the future of cancer treatment. Despite pandemic-driven clinical trial delays across multiple therapy areas, novel immuno-oncology approaches continue […]

What’s driving oncology HTAs in South Korea?

Reimbursement in South Korea depends upon a favorable review by Health Insurance Review Agency  (HIRA), and some therapies may not be reimbursed because of shortcomings from the perspective of HIRA. To help pharma companies plan clinical trials and economic evidence submission in order to achieve favorable access in South Korea, we used the Context Matters […]

What drives the therapy selection test market?

Clarivate medtech expert Sophia Quraishi reviews key factors driving increased demand for premium-priced therapy selection tests.   Therapy selection tests are a form of liquid biopsy, which involve sequencing substrates isolated from bodily fluids, such as blood, saliva or urine. This approach is less invasive, can be used more often and is more cost effective […]

Key ESMO Highlights 2020

As a result of the current COVID-19 pandemic, the annual ESMO Congress was held virtually between 19th and 21st September 2020. Over 2,100 oral presentations and posters were presented, showcasing exciting novel data across oncology, with the ultimate aim of improving cancer patient care. Here DRG/Clarivate highlights the most impactful presentations on drug treatment landscapes. […]

Key Disruptors in The Multiple Myeloma Landscape: 2020 and Beyond

Accelerated innovation in drug design and development is providing diverse treatment options for cancer patients, including hematological malignancies, like multiple myeloma. However, innovation has complicated physicians’ therapy selection and decision making, including how best to sequence treatment across lines of therapy. Thereby contributing to an unmet need for indications like multiple myeloma, that are typically […]